Skip Navigation


Carcinogenesis Advance Access originally published online on February 28, 2008
Carcinogenesis 2008 29(5):1070-1076; doi:10.1093/carcin/bgn054
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
29/5/1070    most recent
bgn054v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Romero, D.
Right arrow Articles by Quintanilla, M.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Romero, D.
Right arrow Articles by Quintanilla, M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2008. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

Functional blockade of Smad4 leads to a decrease in β-catenin levels and signaling activity in human pancreatic carcinoma cells

Diana Romero1,2,*, Maite Iglesias3, Calvin P.H. Vary2 and Miguel Quintanilla1

1 Instituto de Investigaciones Biomedicas Alberto Sols, Arturo Duperier 4, 28029 Madrid, Spain
2 Center for Molecular Medicine, Maine Medical Center Research Institute, 81 Research Drive, Scarborough, ME 04074, USA
3 Departamento de Bioquimica, Universidad Francisco de Vitoria, Ctra Pozuelo-Majadahonda km 1800, 28223 Pozuelo de Alarcon, Madrid, Spain

* To whom correspondence should be addressed. Tel: +1 (207) 885 8272; Fax: +1 (207) 885 8179; Email: romerd{at}mmc.org

In the last several years, many laboratories have tried to unravel the complex signaling mechanisms activated by TGF-β1 in transformed cells. Smad proteins are the principal mediators of the transforming growth factor β (TGF-β) response, but this factor can also activate Smad-independent pathways in different cell types. Our previous studies in murine keratinocytes led to the identification of a cooperation between oncogenic Ras and Smad4 inactivation during malignant progression. We further investigated the function of Smad4 in human pancreatic cancer, in which loss-of-function mutations affecting Smad4 occur with a 50% frequency. Expression of a dominant-negative Smad4 construct in the adenocarcinoma cell line PANC-1 led to increased ubiquitination and proteasomal degradation of β-catenin. Moreover, loss of Smad4 abrogated β-catenin-signaling activity and was associated with a reduction of the tumorigenic potential of PANC-1 cells in scid mice. Although the expression of the dominant-negative Smad4 blocked TGF-β1/Smad2,3-signaling activity, the above-mentioned effects of Smad4 on β-catenin stability were independent of the TGF-β1/Smad2,3-signaling pathway. These findings provide evidence for a cross talk between Smad4 and the Wnt/β-catenin pathway in pancreatic carcinoma cells, suggesting a new role for Smad4 as an attenuator of β-catenin proteasomal degradation.

Abbreviations: APC, adenomatous polyposis coli; TGF-β, transforming growth factor β

Received August 10, 2007; revised February 1, 2008; accepted February 17, 2008.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.